Assembly Biosciences, Inc. (ASMB)

13.15 +0.35 (+2.73%) At close: 04:00PM EDT

Assembly Biosciences, Inc.

Two Tower Place
7th Floor
South San Francisco, CA 94080
United States
833 509 4583
https://www.assemblybio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jason A. Okazaki	CEO, President & Director	1.07M	N/A	1976
Dr. William E. Delaney IV, Ph.D.	Chief Scientific Officer	723.24k	N/A	1972
Dr. Nicole S. White Ph.D.	Chief Manufacturing Officer	616.94k	N/A	N/A
Dr. Uri A. Lopatin M.D.	Co-Founder and Clinical & Scientific Advisor	608.55k	N/A	1972
Dr. Adam Zlotnick	Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board	N/A	N/A	N/A
Jeanette M Bjorkquist	Executive Director of Accounting & Treasury	N/A	N/A	N/A
Shannon Ryan	Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management	N/A	N/A	N/A
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Anuj Gaggar M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1978
Mr. Thomas E. Rollins	Executive Officer	472.55k	N/A	1956

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Corporate governance

Assembly Biosciences, Inc.’s ISS governance QualityScore as of 1 May 2024 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.